Legal & General Group
ZNTL icon

Legal & General Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Legal & General Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5K Buy
+4,848
New +$19.4K ﹤0.01% 3054
2025
Q2 		– Sell
-4,940
Closed -$7.83K – 3558
2025
Q1 		$7.83K Hold
4,940
– – ﹤0.01% 3219
2024
Q4 		$15K Hold
4,940
– – ﹤0.01% 3138
2024
Q3 		$18.2K Sell
4,940
-48,378
-91% -$176K ﹤0.01% 3085
2024
Q2 		$218K Sell
53,318
-3,485
-6% -$38.9K ﹤0.01% 2652
2024
Q1 		$895K Buy
56,803
+1,226
+2% +$16.9K ﹤0.01% 2230
2023
Q4 		$842K Sell
55,577
-186
-0.3% -$2.71K ﹤0.01% 2259
2023
Q3 		$1.12M Buy
55,763
+854
+2% +$21.7K ﹤0.01% 2149
2023
Q2 		$1.55M Buy
54,909
+15,638
+40% +$375K ﹤0.01% 2038
2023
Q1 		$675K Buy
39,271
+1,158
+3% +$23.5K ﹤0.01% 2247
2022
Q4 		$768K Buy
38,113
+393
+1% +$8.45K ﹤0.01% 2223
2022
Q3 		$817K Buy
37,720
+2,229
+6% +$61K ﹤0.01% 2207
2022
Q2 		$998K Buy
35,491
+9,791
+38% +$259K ﹤0.01% 2158
2022
Q1 		$1.19M Buy
25,700
+15,650
+156% +$844K ﹤0.01% 2187
2021
Q4 		$845K Buy
10,050
+1,262
+14% +$97.7K ﹤0.01% 2276
2021
Q3 		$585K Buy
8,788
+4,242
+93% +$245K ﹤0.01% 2379
2021
Q2 		$241K Buy
4,546
+355
+8% +$19K ﹤0.01% 2489
2021
Q1 		$182K Buy
4,191
+98
+2% +$4.22K ﹤0.01% 2473
2020
Q4 		$212K Buy
4,093
+2,728
+200% +$123K ﹤0.01% 2410
2020
Q3 		$45K Sell
1,365
-314
-19% -$11K ﹤0.01% 2730
2020
Q2 		$81K Buy
+1,679
New +$64.4K ﹤0.01% 2589

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Legal & General Group's ZNTL Position: Q2 2026 in Review

Legal & General Group opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 4,848 shares worth $23.5K. The stake represents ﹤0.01% of the portfolio and ranks #3054 among its holdings. This is a return to the name: Legal & General Group previously reported a position in ZNTL as recently as Q1 2025.

Legal & General Group first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $1.55M in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Legal & General Group held 4,848 shares of Zentalis Pharmaceuticals worth $23.5K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Legal & General Group position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3054 holding.
  • Legal & General Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Legal & General Group's Zentalis Pharmaceuticals position peaked at $1.55M in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.